A randomised study of 10 lg/kg/day (single dose) vs 2 Â 5 lg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients
Over the past few years, mobilised autologous peripheral blood progenitor cells (PBPCs) have replaced autologous bone marrow as the major source of haematopoietic support. 1 Regimens used to mobilise PBPCs vary among different centres and clinical settings. At present, mobilisation protocols include the use of granulocyte colonystimulating factor (G-CSF) with or without chemotherapy. 2, 3 When used alone, the optimal dose and schedule of administration for G-CSF are still being defined. In fact, it is not easy to test the role of a G-CSF schedule in the success of mobilisation because it is influenced by several factors: age, bone marrow involvement, prior radiation or prior chemotherapy. Even randomised trials evaluating mobilisation strategies could be confounded by known and unknown patient or disease factors. Therefore, randomised clinical trials with an original (cross-over) design have been reported. 4, 5 High-dose chemotherapy followed by autologous PBPC transplantation was a widely used procedure to treat metastatic and high-risk breast cancer patients. Since reported randomised clinical trials were negative and fraudulent studies were audited, 6 this indication is decreasing. 7 In any case, high-risk breast cancer candidates were a uniform population: young age patients without bone marrow disease and short exposure to chemotherapy. Therefore, they constituted a good model to test new stem cell mobilisation procedures.
Many studies have been devoted to finding a G-CSF dose-effect response. Although some authors have compared a once-daily vs a twice-daily schedule as mobilisation treatment in cancer patients or healthy donors, results have been controversial. [8] [9] [10] [11] [12] [13] We designed a randomised trial in high-risk breast cancer patients comparing collected PBPCs after mobilisation with a single dose of G-CSF (10 mg/kg/ day) or with 5 mg/kg twice daily (split dose). A concurrent pharmacokinetic study was performed in a subgroup of patients to ascertain whether differences in drug availability were associated to its biological function.
Patients and methods
Between 1997 and 1999, a total of 29 consecutive women (Table 1) with high-risk breast cancer (stages II-III) were considered candidates for high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in our institution. The study protocol was approved by the Ethics Committee, and written informed consent was obtained from every patient.
All patients received induction chemotherapy (3-4 courses) with FAC (5-fluorouracil 600 mg/m 2 days 1 and 8, adriamycin 60 mg/m 2 day 1 and cyclophosphamide 600 mg/m 2 day 1, every 3 weeks). After complete haematological recovery, patients were randomised to receive either G-CSF (filgrastim) 10 mg/kg/d at 2000 hours or G-CSF 5 mg/kg at 1200 hours (noon) and at 2000 hours due to patient convenience and day care facilities. The actual weight was considered and no round-up was allowed (doses were adjusted using insulin syringes). G-CSF was administered subcutaneously since day 1 and continued until the targeted PBPCs were collected.
Leukapheresis was started on day 5 if peripheral blood CD34+ cells had reached 10 Â 10 6 /l. All patients had multilumen, indwelling central venous catheters (mostly, Hickman-Broviac 13.5 F). The PBPC collection was performed with a blood cell separator (Fenwall CS-3000 plus, Baxter Healthcare, Deerfield, IL, USA), processing up to 15 l/day of blood. The target PBPC dose to be collected was 3 Â 10 6 CD34+ cells/kg, and leukaphereses were performed daily until that dose was reached.
Flow cytometry. A sample of peripheral blood and apheresis product was incubated with a phycoerythrin (PE)-conjugated anti-CD34 (Inmunotech-581, Marseille, France) coupled to fluorescein isothiocyanate (FITC)-conjugated anti-CD45 (Coulter-KC-56, Hialeah, FL, USA). Analysis was performed on an EPICS-XL flow cytometer (Coulter, Hialeah, FL, USA).
Serum G-CSF assay and pharmacokinetic analysis. In a subgroup of 12 patients, serum G-CSF levels (pg/ml) were measured by sandwich ELISA (R&D Systems, Minneapolis, MN, USA). Serum samples were taken at time points À12, À9, À6 h and just before (time 0) the first apheresis. An area under the plasma concentration-time curve (AUC) was obtained to compare both groups.
Adverse events. All adverse effects were recorded, and a specific pain questionnaire was designed. The scale consisted of five categories: 0 -no pain, 1 -mild pain not needing medication, 2 -moderate pain requiring sporadic medication, 3 -severe pain controlled by regular analgesics, 4 -severe pain, difficult sleep and/or narcotics needed. As a summary measure of variable pain for every patient, an area under curve (AUC) was calculated according to the trapezium rule. /kg of CD34+ cells (favouring the experimental arm, that is, the split dose) between arms was considered as clinically relevant. We calculated that with a sample of 28 patients, the study would have 80% power to detect such a difference in the mean of total CD34+ cells collected, assuming a standard deviation of 2.5 in each group, with the use of a two-group t-test and a one-sided significance level of 0.05.
For continuous variables, mean7s.d. or median values and ranges (minimum and maximum) were calculated. They were compared by parametric (t-test) or nonparametric test (Mann-Whitney) statistics, as appropriate. Proportions were compared using the w 2 test or Fisher's exact test. All reported P-values are two-sided and P-values o0.05 were considered significant. Data were analysed using SPSS version 9.0 software (SPSS, Inc., Chicago, IL, USA).
Results
From July 1997 to June 1999, 29 patients were randomised (15 to the single dose and 14 to the split dose). All patients were treated according to the assigned dose. One patient (single-dose group) did not achieve a minimal concentration of CD34+ cells in peripheral blood on day 5; therefore, a bone marrow harvest was performed. This patient was considered as a mobilisation failure and was not included in further analyses. The two groups were well balanced for the most relevant clinical features influencing mobilisation yield (Table 1) .
Collection and progenitor cell counts. No significant differences were observed between groups regarding apheresis parameters: the median number of aphereses was 2 (range 1-4) in the single-dose group and 2 (2-3) in the split-dose group (P ¼ 0.5), with a median of 30 l of total processed blood for both arms (P ¼ 0.4). The total number of CD34+ cells collected was higher in the split-dose group than in the single-dose group with means of 7.173.2 Â 10 6 / kg vs 5.671.7 Â 10 6 /kg and medians of 7.4 (2.9-12.2) and 5.8 (3.1-8.3), respectively (P-value 0.12 by t-test and 0.26 by Mann-Whitney test). Therefore, the difference between /kg favouring split-dose group with 95% confidence interval between À0.5 and 3.5 (medians difference of 1.6 Â 10 6 /kg). The mean of CD34+ cells collected after the first apheresis was 3.1 Â 10 6 /kg for the single-dose group and 3.9 Â 10 6 /kg for the split-dose group (P ¼ 0.24) with medians of 3.1 (1.3-5.6) and 3.5 (1.2-8.6), respectively. A positive correlation was observed between the total of CD34+ cells collected and the CD34+ cells collected in the first apheresis (r ¼ 0.88, P ¼ 0.0001). Among the 15 patients who reached 3 Â 10 6 /kg CD34+ cells in the first procedure, seven had been treated with a single dose and eight with the split dose. The number of circulating CD34+ cells in peripheral blood before the first apheresis was higher for the split-dose group (means of 79.7 vs 59.2 Â 10 6 /l) (P ¼ 0.14). Neutrophil and platelet engraftment: The interval in days to neutrophil and platelet engraftment was identical, with means of 10.9 and 10.6, respectively, for the split-dose group and 11 and 10.6 for the single-dose group.
G-CSF pharmacokinetic analysis: Pharmacokinetic parameters in the subgroup of patients studied (seven treated with a single dose and five with split dose) were scheduledependent (Table 2) . At tÀ12 (12 h before the first apheresis), there was a higher G-CSF serum concentration in the split-dose group (mean7s.d.) (18 328 pg/ml77468) than the single-dose group (9167653) (P ¼ 0.006). In fact, the first group received a G-CSF dose at 1200 hours (8 h before) and the single daily dose group received a dose 24 h before. However, this difference disappeared after 3 h. The area under curve (AUC/-12-0 h) with the single dose achieved a 27% higher value than that obtained with the split dose, but this difference was not significant (429 700773 520 vs 337 0007126 970 pg/ml/h, P ¼ 0.2). No significant changes were observed in white blood cell (WBC) counts in both groups during the 12 h before the first apheresis (Table 2) .
Adverse effects: A total of 18 patients (11 in the singledose group and seven in the split-dose group) answered their pain questionnaire. All scores were higher for the split-dose group, reflecting higher mean pain value (1.6 vs 0.8, P ¼ 0.07), maximal scoring (2.4 vs 1.2, P ¼ 0.05) and broader AUC (pain through time, 6.9 vs 3.4, P ¼ 0.05) for this group.
Discussion
Mobilisation of PBPC from bone marrow is a complex biological process regulated by multiple adhesive interactions between progenitor cells and bone marrow extracellular matrix, including release of proteases 15 and modulation of different cellular antigens. 16 This process is influenced by chemotherapy and/or haematopoietic growth factors. The optimal combination of these factors or the schedule of administration remains to be determined.
In this randomised study, we aimed to show a significant mobilisation improvement, splitting the usual G-CSF dose of 10 mg/kg/day into two daily subcutaneous administrations of 5 mg/kg during 4 days, in homogeneously treated high-risk breast cancer patients.
The primary end point of increasing the total number of CD34+ cells collected to 2.5 Â 10 6 /kg was not achieved. This amount was decided based on previous reports (Table 3 ) and because we considered such an increase as the smallest difference with clinical relevance. Nevertheless, a nonstatistically significant increase was observed (difference between means of 1.5 Â 10 6 /kg CD34+ cells, between medians of 1.6 Â 10 6 ) favouring the split-dose schedule. However, a total of 72 patients would have to be enrolled in the study to test the value of this smaller difference, if other statistical parameters (standard deviations, power of 80% and one-sided test) were maintained.
Our patients constituted a consistent and homogeneous group. Therefore, some factors influencing mobilisation such as, oncologic disease, age and prior treatment with chemotherapy, do not seem to affect the interpretation of the results. Moreover, random allocation yields more comparable groups because confounding variables are probably balanced.
One previous randomised study in breast cancer patients published as an abstract 12 (Table 3) , showed a mean of 10.6 Â 10 6 /kg total CD34+ cells collected in the G-CSF split-dose arm and 6 Â 10 6 /kg in the single-dose arm (P ¼ 0.02). Intervals from the last G-CSF dose to the first apheresis or differences following first aphereses were not reported. Of particular interest is a randomised study testing the advantage of splitting G-CSF for PBPC mobilisation in healthy donors. 10 These authors found a significant difference favouring split-dose arm after first apheresis (Table 3) . Other published studies are retrospective comparisons (cohorts) and limited conclusions can be made.
The present study showed no statistically significant advantage in total CD34+ cell collection after splitting the G-CSF dose, neither in the number of circulating CD34+ cells before the first apheresis nor in the number of CD34+ cells collected after the first day. In our study, the interval between G-CSF doses in the split-dose group was not 12 h. In addition, no G-CSF dose was given 2-3 h before Table 2 Changes in serum G-CSF level and WBC counts 1 Â 10 mg/kg, n=7 2 Â 5 mg/kg, n=5 Study of single vs split dose of G-CSF as mobilisation regimen R Carrión et al apheresis as in other reports 9,11 which had controversial results. Therefore, the influence of such differences in our results is difficult to evaluate.
Our data show that serum G-CSF concentration before the first apheresis was not influenced by splitting the dose (Table 2) . However, during the 12 h before first apheresis some differences were observed in serum G-CSF levels depending on the schedule of G-CSF administration. However, no significant differences could be seen between WBC counts in both groups during this interval. We can hypothesise that most of the biologic effects of G-CSF on CD34+ cells release from bone marrow to peripheral blood have taken place before this 12 h analysed interval.
Significant differences were observed in bone pain scores between both groups (worse for the split-dose arm) in contrast with previous studies that did not find differences with similar dose ranges. 9, 11, 13 These data cannot be explained as a reflection of the higher number of skin punctures and could be associated with a more continuous biological effect on the bone marrow. On the other hand, a subjective perception of more pain related to more frequent G-CSF administration cannot be ruled out.
In summary, our study on high-risk breast cancer patients found no statistically significant improvement in CD34+ cell mobilisation capacity by splitting the usual G-CSF dose. Nevertheless, improving the yield could be of interest for patients with a low mobilisation potential (socalled ''poor mobilisers'') as well as for those in which a high CD34 + collection number is required for further in vitro manipulations, such as cellular purging or gene therapy procedures. 17 New strategies of haematopoietic stem cell mobilisation should be tested in randomised clinical trials, either involving healthy donors 18 or homogeneously treated patients, in order to improve the yield of CD34+ cells and avoid confounding factors. Furthermore, additional effort should be focused to find new biologic markers to closely follow this partially understood process.
